Updated March 25, 2016
FAMILY/DRUG NAME | MECHANISM | COMPANY | STATUS |
Interferons - Mimic naturally-occurring, infection-fighting immune substances produced in the body | |||
Intron A (Interferon alfa-2b) | Immunomodulator | Merck, Whitehouse Station, NJ | FDA Approved 1991 |
Pegasys (Peginterferon alfa-2a) | Immunomodulator | Genentech, South San Francisco, CA | FDA Approved 2005 |
There are other brands of interferon approved for HCV treatment, but they have not been FDA-approved for HBV: Wellferon (Glaxo), Roferon(Hoffman-La Roche), and Infergen (Amgen) | |||
Nucleoside Analogues - Interfere with the viral DNA polymerase enzyme used for hepatitis B virus reproduction | |||
Epivir-HBV (Lamivudine) | Inhibits viral DNA polymerase | GlaxoSmithKline, Philadelphia, PA | FDA Approved 1998 |
Hepsera (Adefovir Dipivoxil) | Inhibits viral DNA polymerase | Gilead Sciences, Foster City, CA | FDA Approved 2002 |
Baraclude (Entecavir) | Inhibits viral DNA polymerase | Bristol-Myers Squibb,Princeton, NJ | FDA Approved 2005 |
Tyzeka (Telbivudine) | Inhibits viral DNA polymerase | Novartis, Switzerland | FDA Approved 2006 |
Viread (Tenofovir) | Inhibits viral DNA polymerase | Gilead Sciences, Foster City, CA | FDA Approved 2008 |
Clevudine (L-FMAU) | Inhibits viral DNA polymerase | Bukwang, South Korea Eisai, Japan | Approved S. Korea 2006 (Levovir) |
Tenofovir alafenamide (TAF) | Prodrug of Tenofovir | Gilead Sciences, Foster City, CA | Phase III |
CMX157 | Prodrug of Tenofovir | ContraVir Pharmaceuticals, Edison, NJ | Phase II |
AGX-1009 | Prodrug of Tenofovir | Cinkate Pharma | Phase I, China |
Non-Nucleoside Antivirals - Interfere with proteins involved in viral reproduction | |||
Myrcludex B | Entry Inhibitor | Hepatera, Russia with Myr-GmbH, Germany | Phase II for HBV and HDV |
ARC520 | RNAi gene silencer | Arrowhead Research, Pasadena, CA | Phase II/III |
NVR 3-778 | Capsid inhibitor | Novira Therapeutics, Doylestown, PA | Phase IIa |
Morphothiadine mesilate (GLS4) | Capsid inhibitor | Sunshine Lake Pharma of HEC, China | Phase II |
IONIS-HBVRx | Antisense drug | Ionis Pharma, Carlsbad, CA | Phase II |
SB 9200 HBV | RIG-1 and NOD2 agonist | Spring Bank Pharma, Milford, MA | Phase II |
Rep 2139-Ca | HBsAg release inhibitor | REPLICor Inc., Canada | Phase II |
ARB-1467 | RNAi gene silencer | Tekmira, Canada | Phase II |
AIC 649 | Capsid Inhibitor | AiCuris, Germany | Phase I |
IONIS-HBV-LRx | Antisense drug | Ionis Pharma (w/ GSK), Carlsbad, CA | Phase I |
EYP001 | FXR agonist | Enyo Pharma | Phase I |
CpAMS | HBV Core Protein | Assembly Biosciences, NY, NY | Preclinical |
ALN-HBV | RNAi gene silencer | Alnylam, | Preclinical |
CPI-431-32 | Cyclophilin inhibitor | Ciclofilin Pharma, | Preclinical |
Hepbarna | RNAi gene silencing | Benitec, Australia | Preclinical |
ARB-1740 | Gene silencer | Arbutus Biopharma Canada | Preclinical |
Non-Interferon Immune Enhancers - Boost T-cell infection-fighting immune cells and natural interferon production | |||
ABX 203 | Therapeutic vaccine | ABIVAX, Paris, France | Phase IIb/III |
GS-4774 | Therapeutic vaccine | Gilead Sciences with Globe Immune, Louisville, CO | Phase II |
GS-9620 | TLR7 agonist | Gilead Sciences, Foster City, CA | Phase II |
RG7795 (formerly ANA773) | TLR7 agonist | Roche, Switzerland | Phase II |
INO-1800 | Therapeutic vaccine | Inovio, Blue Bell, PA | Phase I |
NCT01641536 | Therapeutic vaccine | Ichor Medical Systems (w/Janssen), San Diego, CA | Phase I |
TG 1050 | Immunotherapeutic | Transgene, Shanghai | Phase I |
ARB-1598 | TLR9 agonist | Arbutus Biopharma Canada | Phase I |
Hepatitis Delta Virus (HDV) Drug Watch | |||
Myrcludex B | Entry Inhibitor (Targeting NTCP) | Hepatera, Russia with Myr-GmbH, Germany | "Orphan Drug Designation" by US FDA and EMA for HDV |
Lonafarnib | Prenylation Inhibitor | Eiger BioPharmaceuticals, Palo Alto, CA | Phase II for HDV |
Rep 2139 | HBsAg Release Inhibitor | REPLICor, Canada | Phase II for HDV |
欢迎光临 肝胆相照论坛 (http://hbvhbv.info/forum/) | Powered by Discuz! X1.5 |